Syndax Pharmaceuticals

Syndax Pharmaceuticals

SNDX· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +58.9% in FY2025

Michael A. Metzger is the CEO of Syndax Pharmaceuticals and was paid $7.1M in FY2025 (Dec), down 8%.

Pay$100 in the stock at the end of FY20 → $94
CEO pay is from each Syndax Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1Michael A. MetzgerFY2025
  2. 2Nick Botwood, M.B.B.S.FY2025
  3. 3Keith A. GoldanFY2025
  4. 4Luke J. AlbrechtFY2025
  5. 5Steve ClosterFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Syndax Pharmaceuticals paid its 5 named executives $16.9M in total in FY2025 (Dec). CEO Michael A. Metzger was paid $7.1M of that.

Name
Michael A. MetzgerChief Executive Officer
Nick Botwood, M.B.B.S.Head of Research & Development, Chief Medical OfficerNot disclosedNot disclosed
Keith A. GoldanChief Financial Officer
Luke J. AlbrechtGeneral Counsel and Secretary
Steve ClosterChief Commercial OfficerNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers22

See all

The FY2025 (Dec) proxy of Syndax Pharmaceuticals names 22 peer companies for pay. Pay versus performance data of Syndax Pharmaceuticals for that year is not on file, so it has no rank.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board4

See all
  • Dennis G. PodlesakChair · 17 yr on the boardIndependentAudit, Compensation, Nominating and Corporate Governance (Chair)—Paid as an executive
  • Keith A. KatkinDirector · 8 yr on the boardIndependentAudit, Compensation (Chair), Nominating and Corporate Governance, Science and Technology—Paid as an executive
  • Pierre LegaultDirector · 8 yr on the boardIndependentAudit (Chair), Compensation, Nominating and Corporate Governance—Paid as an executive
  • Jennifer JarrettDirector · 7 yr on the boardIndependentNominating and Corporate Governance, Science and Technology—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    Syndax Pharmaceuticals Division head pay fell 40% to $2.1M. The stock rose 59% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Syndax Pharmaceuticals CFO pay fell 13% to $2.5M. The stock rose 59% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Syndax Pharmaceuticals President pay fell 25% to $2.9M. The stock fell 39% in FY2024 (Dec).
    DEF 14A
  4. Pay
    Syndax Pharmaceuticals CEO pay fell 16% to $7.7M. The stock fell 39% in FY2024 (Dec).
    DEF 14A
  5. Pay
    Syndax Pharmaceuticals CEO pay rose 23% to $4.1M. The stock rose 16% in FY2022 (Dec).
    DEF 14A
  6. Board
    Dennis G. Podlesak joined the board of Syndax Pharmaceuticals. Dennis G. Podlesak sits on no other public board.
    3
  7. Pay
    Syndax Pharmaceuticals CEO pay rose 122% to $9.1M. The stock fell 15% in FY2023 (Dec).
    DEF 14A
  8. Pay
    Syndax Pharmaceuticals General counsel pay rose 76% to $2.6M. The stock fell 15% in FY2023 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AApr 30, 2026FY2025
Annual report10-KFeb 26, 2026FY2025
Proxy statementDEF 14AApr 1, 2025FY2024
Annual report10-KMar 3, 2025FY2024
Proxy statementDEF 14AApr 2, 2024FY2023
Annual report10-KFeb 27, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data